AI Article Synopsis
- PARP inhibitors (PARPi) are becoming standard treatments in oncology, particularly for different types of breast cancer, but there’s a need for better ways to identify which patients will respond to these treatments.
- The case study highlights a 57-year-old woman with hormone-receptor-positive, HER2-negative metastatic breast cancer who benefited from talazoparib due to her specific genetic mutation.
- This scenario underscores the significance of a multidisciplinary approach to manage patients with brain metastases and emphasizes the role of personalized treatment based on biomarkers.
Article Abstract
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448731 | PMC |
| http://dx.doi.org/10.36401/JIPO-22-33 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!